These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 35093871)

  • 41. Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models.
    Kawaguchi K; Igarashi K; Li S; Han Q; Tan Y; Miyake K; Kiyuna T; Miyake M; Murakami T; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Unno M; Eilber FC; Hoffman RM
    Oncotarget; 2018 Jan; 9(1):915-923. PubMed ID: 29416666
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oral Recombinant Methioninase Sensitizes a Bladder Cancer Orthotopic Xenograft Mouse Model to Low-dose Cisplatinum and Prevents Metastasis.
    Sun YU; Nishino H; Sugisawa N; Yamamoto J; Hamada K; Zhu G; Lim HI; Hoffman RM
    Anticancer Res; 2020 Nov; 40(11):6083-6091. PubMed ID: 33109546
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral dosing of Recombinant Methioninase Is Associated With a 70% Drop in PSA in a Patient With Bone-metastatic Prostate Cancer and 50% Reduction in Circulating Methionine in a High-stage Ovarian Cancer Patient.
    Han Q; Tan Y; Hoffman RM
    Anticancer Res; 2020 May; 40(5):2813-2819. PubMed ID: 32366428
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reduced Malignancy of Super Methotrexate-resistant Osteosarcoma Cells With Dihydrofolate Reductase Amplification Despite Paradoxical Gain of Oncogenic PI3K/AKT/mTOR and c-MYC expression.
    Aoki Y; Kubota Y; Masaki N; Obara K; Tome Y; Bouvet M; Nishida K; Hoffman RM
    Anticancer Res; 2024 Jul; 44(7):2787-2792. PubMed ID: 38925854
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Novel Anionic-phosphate-platinum Complex Effectively Targets a Cisplatinum-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
    Igarashi K; Kawaguchi K; Yamamoto N; Hayashi K; Kimura H; Miwa S; Higuchi T; Taniguchi Y; Yonezawa H; Araki Y; Morinaga S; Misra S; Nelson SD; Dry SM; Li Y; Odani A; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Genomics Proteomics; 2020; 17(3):217-223. PubMed ID: 32345663
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Combination of Methioninase and Ethionine Exploits Methionine Addiction to Selectively Eradicate Osteosarcoma Cells and Not Normal Cells and Synergistically Down-regulates the Expression of
    Aoki Y; Kubota Y; Han Q; Masaki N; Obara K; Bouvet M; Chawla SP; Tome Y; Nishida K; Hoffman RM
    Cancer Genomics Proteomics; 2023 Dec; 20(6suppl):679-685. PubMed ID: 38035708
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Eribulin Inhibits Osteosarcoma in a Clinically-accurate Bone-tumor-insertion PDOX Mouse Model.
    Wu NF; Yamamoto J; Aoki Y; Bouvet M; Hoffman RM
    Anticancer Res; 2021 Apr; 41(4):1779-1784. PubMed ID: 33813382
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lowering and Stabilizing PSA Levels in Advanced-prostate Cancer Patients With Oral Methioninase.
    Han Q; Hoffman RM
    Anticancer Res; 2021 Apr; 41(4):1921-1926. PubMed ID: 33813397
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model.
    Wu NF; Yamamoto J; Aoki Y; Masaki N; Samonte C; Wu J; Bouvet M; Hoffman RM
    Anticancer Res; 2021 Oct; 41(10):4715-4718. PubMed ID: 34593419
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model.
    Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
    Sci Rep; 2021 Apr; 11(1):8583. PubMed ID: 33883561
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model.
    Igarashi K; Kawaguchi K; Li S; Han Q; Tan Y; Gainor E; Kiyuna T; Miyake K; Miyake M; Higuchi T; Oshiro H; Singh AS; Eckardt MA; Nelson SD; Russell TA; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
    Oncotarget; 2018 Apr; 9(27):19263-19272. PubMed ID: 29721200
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
    Miyake K; Kiyuna T; Kawaguchi K; Higuchi T; Oshiro H; Zhang Z; Wangsiricharoen S; Razmjooei S; Li Y; Nelson SD; Murakami T; Hiroshima Y; Matsuyama R; Bouvet M; Chawla SP; Singh SR; Endo I; Hoffman RM
    Cancer Chemother Pharmacol; 2019 May; 83(5):809-815. PubMed ID: 30758647
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model.
    Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Belt P; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2019 Sep; 39(9):4781-4786. PubMed ID: 31519579
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synergy of oral recombinant methioninase (rMETase) and 5-fluorouracil on poorly differentiated gastric cancer.
    Miyake M; Miyake K; Han Q; Igarashi K; Kawaguchi K; Barangi M; Kiyuna T; Sugisawa N; Higuchi T; Oshiro H; Zhang Z; Razmjooei S; Bouvet M; Endo I; Hoffman RM
    Biochem Biophys Res Commun; 2023 Feb; 643():48-54. PubMed ID: 36586158
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
    Kiyuna T; Tome Y; Miyake K; Murakami T; Oshiro H; Igarashi K; Kawaguchi K; Hsu J; Singh M; Li Y; Nelson S; Bouvet M; Singh SR; Kanaya F; Hoffman RM
    Anticancer Res; 2019 Sep; 39(9):4775-4779. PubMed ID: 31519578
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model.
    Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2019 Aug; 39(8):4079-4084. PubMed ID: 31366491
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vivo pharmacological evaluation and efficacy study of methotrexate-encapsulated polymer-coated layered double hydroxide nanoparticles for possible application in the treatment of osteosarcoma.
    Ray S; Saha S; Sa B; Chakraborty J
    Drug Deliv Transl Res; 2017 Apr; 7(2):259-275. PubMed ID: 28050892
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Osteosarcoma of the Breast in a Patient Derived Orthotopic Xenograft (PDOX) Mouse Model Is Arrested by both Cisplatinum and Eribulin.
    Masaki N; Wu NF; Aoki Y; Yamamoto J; Miyazaki J; Hoffman RM
    In Vivo; 2021; 35(6):3107-3110. PubMed ID: 34697141
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma.
    Lee DH; Thoennissen NH; Goff C; Iwanski GB; Forscher C; Doan NB; Said JW; Koeffler HP
    Cancer Lett; 2011 Jul; 306(2):161-170. PubMed ID: 21440986
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adjuvant Oral Recombinant Methioninase Inhibits Lung Metastasis in a Surgical Breast-Cancer Orthotopic Syngeneic Model.
    Sugisawa N; Hamada K; Han Q; Yamamoto J; Sun YU; Nishino H; Kawaguchi K; Bouvet M; Unno M; Hoffman RM
    Anticancer Res; 2020 Sep; 40(9):4869-4874. PubMed ID: 32878774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.